Новые данные о молекулярных мишенях тамоксифена, отличных от рецепторов эстрогенов, и их клиническая значимость

Тамоксифен - первый таргетный препарат, который по-прежнему занимает лидирующую позицию в лечении рака молочной железы. Экспериментальные работы последних лет раскрывают всё новые и новые биологические эффекты при воздействии тамоксифена на опухолевые клетки. Данная публикация является продолжением опубликованного в 2012 г. обзора данных литературы, демонстрирующих многообразие эффектов тамоксифена, не связанных с его взаимодействием с рецепторами эстрогенов. Так, выявлен обширный спектр мишеней препарата, которые являются ключевыми точками сигнальных каскадов, активирующих пролиферацию клеток, определяют агрессивность течения опухолевого процесса и чувствительность к химиотерапии. Описаны клинические исследования применения тамоксифена, основанием для которых явилось воздействие препарата на мишени, отличные от рецепторов эстрогенов. Кроме того, в обзор включены данные о противовирусной, противобактериальной, противогрибковой и противопаразитарной активности тамоксифена.

тамоксифен, протеинкиназа С, апоптоз, антиангиогенное действие, метастазирование, лекарственная устойчивость, противоопухолевое действие

1. Bogush T., Dudko E., Bogush E. et al. Tamoxifen non-estrogen receptor mediated molecular targets. Oncol Rev2012; 6: 2: e15.

2. Balça-Silva J., Matias D., do Carmo A. et al. Tamoxifen in combination with temozolomide induce a synergistic inhibition of PKC-pan in GBM cell lines. Biochim Biophysic Acta 2015; 1850: 4: 722-732.

3. Yang L., Yuan X., Wang J. et al. Radiosensitization of human glioma cells by tamoxifen is associated with the inhibition of PKC-i activity in vitro. Oncol Lett 2015; 10: 1: 473-478.

4. Couldwell W.T., Hinton D.R., Surnock A.A. et al. Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen. Clinical cancer research: an Official J American Association for Cancer Research 1996; 2: 4: 619-622.

5. Chamberlain M.C., Kormanik P.A. Salvage chemotherapy with tamoxifen for recurrent anaplastic astrocytomas. Arch Neurol 1999; 56: 6: 703-708.

6. Mastronardi L., Puzzilli F., Couldwell W. T. et al. Tamoxifen and carboplatin combinational treatment of high-grade gliomas. Results of a clinical trial on newly diagnosed patients. J Neuro-Oncol 1998; 38: 1: 59-68.

7. Tang P., Roldan G., Brasher P. M. et al. A phase II study of carboplatin and chronic high-dose tamoxifen in patients with recurrent malignant glioma. J Neuro-Oncol 2006; 78: 3: 311-316.

8. Cristofori A., Carrabba G., Lanfranchi G. et al. Continuous tamoxifen and dose-dense temozolamide in recurrent glioblastoma. Anticancer Res 2013; 33: 8: 3383-3389.

9. Kohli L., Kaza N., Coric T. et al. 4-Hydroxytamoxifen induces autophagic death through K-Ras degradation. Cancer Res 2013; 73: 14: 4395-4405.

10. Xie X., Wu M. Y., Shou L. M. et al. Tamoxifen enhances the anticancer effect of cantharidin and norcantharidin in pancreatic cancer cell lines through inhibition of the protein kinase C signaling pathway. Oncol Lett 2015; 9: 2: 837-844.

11. Keating J.J., Johnson P.J., Cochrane A.M. et al. A prospective randomised controlled trial of tamoxifen and cyproterone acetate in pancreatic carcinoma. Brit J Cancer 1989; 60: 5: 789-792.

12. Theve N.O., Pousette A., Carlström K. Adenocarcinoma of the pancreas-a hormone sensitive tumor? A preliminary report on Nolvadex treatment. Clin Oncol 1983; 9: 3: 193-197.

13. Wong A., Chan A. Survival benefit of tamoxifen therapy in adenocarcinoma of pancreas. A case-control study. Cancer 1993; 71: 7: 2200-2203.

14. Morita S., Motohara T., Ogawa K., Horimi T. Hormone therapy using tamoxifen in unresectable carcinoma of the pancreas-preliminary study. Nihon Igaku Höshasen Gakkai zasshi. Nipp Acta Radiol 1992; 52: 12: 1686-1688.

15. Lamy R., Conroy T., Brunaud L., Bresler L. Tamoxifen for metastatic pancreatic adenocarcinoma: a complete response. Gastroenterol Clin Biol 2001; 25: 10: 912-913.

16. Wenger F.A., Zieren H.U., Jacobi C.A., Müller J.M. Hormone therapy of postoperative recurrent pancreatic carcinoma with octreotide and tamoxifen. Langenbecks Archiv Für Chirurgie. Supplement. Kongressband 1998; 115: 1348-1350.

17. Rosenberg L., Barkun A.N., Denis M.H., Pollak M. Low dose octreotide and tamoxifen in the treatment of adenocarcinoma of the pancreas. Cancer 1995; 75: 1: 23-28.

18. Patel B.M., Desai V.J. Beneficial role of tamoxifen in experimentally induced cardiac hypertrophy. Pharmacol Reports 2014; 66: 2: 264-272.

19. Kuo J.R., Wang C.C., Huang S.K., Wang S.J. Tamoxifen depresses glutamate release through inhibition of voltage-dependent Ca2+ entry and protein kinase Ca in rat cerebral cortex nerve terminals. Neurochem Internation 2012; 60: 2: 105-114.

20. Steckert A.V., Valvassori S.S., Mina F. et al. Protein kinase C and oxidative stress in an animal model of mania. Curr Neurovascul Res 2012; 9: 1: 47-57.

21. Armani F., Andersen M. L., Galduróz J.C. Tamoxifen use for the management of mania: a review of current preclinical evidence. Psychopharmacology 2014; 231: 4: 639-649.

22. Smith C.P., Oh J.D., Bibbiani F. et al. Tamoxifen effect on L-DOPA induced response complications in parkinsonian rats and primates. Neuropharmacology 2007; 52: 2: 515-526.

23. Li Z, Wang N., Fang J. et al. Role of PKC-ERK signaling in tamoxifen-induced apoptosis and tamoxifen resistance in human breast cancer cells. Oncol Reports 2012; 27: 6: 1879-1886. Выполнено при поддержке РФФИ (гранты 15-04-06991-а и 16-34-01049-мол-а) и гранта Президента Российской Федерации МК-7709.2016.7.

24. Shim J.S., Li R. J., Lv J. et al. Inhibition of angiogenesis by selective estrogen receptor modulators through blockade of cholesterol trafficking rather than estrogen receptor antagonism. Cancer Lett 2015; 362: 1: 106-115.

25. Garvin S., Nilsson U.W., Dabrosin C. Effects of oestradiol and tamoxifen on VEGF, soluble VEGFR-1, and VEGFR-2 in breast cancer and endothelial cells. Brit J Cancer 2005; 93: 9: 1005-1010.

26. Morad S.A., Cabot M.C. Tamoxifen regulation of sphingolipid metabolism-therapeutic implications. Biochim Biophys Acta 2015; 1851: 9: 1134-1145.

27. Morad S.A., Madigan J.P., Levin J.C. et al. Tamoxifen magnifies therapeutic impact of ceramide in human colorectal cancer cells independent of p53. Biochem Pharmacol 2013; 85: 8: 1057-1065.

28. Ribeiro M.P., Santos A.E., Custodio J.B. Mitochondria: the gateway for tamoxifen-induced liver injury. Toxicology 2014; 323: 10-18.

29. Li Z., Chen J., Lei T., Zhang H. Tamoxifen induces apoptosis of mouse microglia cell line BV-2 cells via both mitochondrial and death receptor pathways. J Huazhong Univer Science Technol. Medical Sciences 2012; 32: 2: 221-226.

30. Todorova V.K., Kaufmann Y., Luo S., Klimberg V.S. Tamoxifen and raloxifene suppress the proliferation of estrogen receptor-negative cells through inhibition of glutamine uptake. Cancer Chemother Pharmacol 2011; 67: 2: 285-291.

31. Hwang J.J., Kim H.N., Kim J. et al. Zinc(II) ion mediates tamoxifen-induced autophagy and cell death in MCF-7 breast cancer cell line. BioMetals 2010; 23: 6: 997-1013.

32. Cho K.S., Yoon Y.H., Choi J.A. et al. Induction of autophagy and cell death by tamoxifen in cultured retinal pigment epithelial and photoreceptor cells. Invest Ophthalmol Visual Sci 2012; 53: 9: 5344-5353.

33. Prather P.L., FrancisDevaraj F., Dates C.R. et al. CB1 and CB2 receptors are novel molecular targets for Tamoxifen and 4OH-Tamoxifen. Biochem Biophys Res Com 2013; 441: 2: 339-343.

34. Herrera J.L., Diaz M., Hernandez-Fernaud J.R. et al. Voltage-dependent anion channel as a resident protein of lipid rafts: post-transductional regulation by estrogens and involvement in neuronal preservation against Alzheimer's disease. J Neurochem 2011; 116: 5: 820-827.

35. Pawar P., Ma L., Byon C.H. et al. Molecular mechanisms of tamoxifen therapy for cholangiocarcinoma: role of calmodulin. Clin Cancer Res: Official J Amer Assoc Cancer Res 2009; 15: 4: 1288-1296.

36. Jing G., Yuan K., Turk A.N. et al. Tamoxifen enhances therapeutic effects of gemcitabine on cholangiocarcinoma tumorigenesis. Lab Investigat; J Techn Meth Pathol 2011; 91: 6: 896-904.

37. Cimica V., Smith M.E., Zhang Z. et al. Potent inhibition of rhabdoid tumor cells by combination of flavopiridol and 4OH-tamoxifen. BMC Cancer 2010; 10: 634.

38. Perez B., Henriquez C., Sarmiento J. et al. Tamoxifen as a new therapeutic tool for neutrophilic lung inflammation. Respirology 2016; 21: 1: 112-118.

39. Sarmiento J., Perez B., Morales N. et al. Apoptotic effects of tamoxifen on leukocytes from horse peripheral blood and bronchoalveolar lavage fluid. Vet Res Com 2013; 37: 4: 333-338.

40. Mao J., Yuan J., Wang L. et al. Tamoxifen inhibits migration of estrogen receptor-negative hepatocellular carcinoma cells by blocking the swelling-activated chloride current. J Cell Physiol 2013; 228: 5: 991-1001.

41. Ribeiro M.P., Silva F.S., Paixâo J. et al. The combination of the antiestrogen endoxifen with all-trans-retinoic acid has anti-proliferative and anti-migration effects on melanoma cells without inducing significant toxicity in non-neoplasic cells. Europ J Pharmacol 2013; 715: 1-3: 354-362.

42. Mao Z., Zhou J., Luan J. et al. Tamoxifen reduces P-gp-mediated multidrug resistance via inhibiting the PI3K/Akt signaling pathway in ER-negative human gastric cancer cells. Biomed Pharmacother 2014; 68: 2: 179-183.

43. Nicolao M.C., Elissondo M.C. et al. In vitro and in vivo effects of tamoxifen against larval stage Echinococcus granulosus. Antimicrob Agents Chemother 2014; 58: 9: 5146-5154.

44. Miguel D.C., Yokoyama-Yasunaka J.K., Andreoli W.K. et al. Tamoxifen is effective against Leishmania and induces a rapid alkalinization of para-sitophorous vacuoles harbouring Leishmania (Leishmania) amazonensis amastigotes. J Antimicrob Chemother 2007; 60: 3: 526-534.

45. Miguel D.C., Zauli-Nascimento R.C., Yokoyama-Yasunaka J.K. et al. Tamoxifen as a potential antileishmanial agent: efficacy in the treatment of Leishmania braziliensis and Leishmania chagasi infections. J Antimicrob Chemother 2009; 63: 2: 365-368.

46. Butts A., Koselny K., Chabrier-Rosello Y. et al. Estrogen receptor antagonists are anti-cryptococcal agents that directly bind EF hand proteins and synergize with fluconazole in vivo. mBio 2014; 5: 1: e00765-00713.

47. Zhang X., Fang Y., Jaiseng W. et al. Characterization of tamoxifen as an antifungal agent using the yeast Schizosaccharomyces pombe model organism. Kobe J Med Sci 2015; 61: 2: E54-63.

48. Jang W.S., Kim S., Podder B. et al. Anti-mycobacterial activity of tamoxifen against drug-resistant and intra-macrophage Mycobacterium tuberculosis. J Microbiol Biotechnol 2015; 25: 6: 946-950.

49. Murakami Y., Fukasawa M., Kaneko Y. et al. Selective estrogen receptor modulators inhibit hepatitis C virus infection at multiple steps of the virus life cycle. Microb Infect/Institut Pasteur 2013; 15: 1: 45-55.

50. Jordan V.C. Tamoxifen as the first successful targeted therapy in cancer: the gift that kept on giving. Breast Cancer Manag 2014; 3: 4: 321-326.

51. Singh M.N., Martin-Hirsch P.L., Martin F.L. The multiple applications of tamoxifen: an example pointing to SERM modulation being the aspirin of the 21st century. Med Sci Monitor: Internat Med J Exper Clin Res 2008; 14: 9: RA144-148.